Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.45 |
| ▸ | FNTA | P49354 | 7/20 | 0.44 |
| ▸ | FNTB | P49356 | 7/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550853 | 0.89 | BACE1 (0.47) | BACE1FNTAFNTBCTSD | |
| SCHEMBL29445196 | 0.89 | BACE1 (0.46) | BACE1FNTAFNTBCTSDBACE2 | |
| SCHEMBL29445230 | 0.88 | FNTA (0.43) | FNTAFNTB | |
| SCHEMBL30052925 | 0.87 | BACE1 (0.48) | BACE1FNTAFNTBCTSD | |
| SCHEMBL29688977 | 0.84 | FNTA (0.42) | BACE1FNTAFNTBCTSDBACE2 | |
| SCHEMBL29645141 | 0.84 | FNTA (0.49) | BACE1FNTAFNTBCTSD | |
| SCHEMBL30052493 | 0.83 | FNTA (0.55) | BACE1FNTAFNTB | |
| SCHEMBL30279341 | 0.82 | BACE1 (0.40) | BACE1FNTAFNTBCTSD | |
| SCHEMBL30272510 | 0.81 | FNTA (0.52) | BACE1FNTAFNTBCTSDBACE2 | |
| SCHEMBL31683255 | 0.80 | FNTA (0.41) | BACE1FNTAFNTBCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | BACE1 1547/4885FNTA 721/4885FNTB 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.